Akili, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 09:12 pm
Share
Akili, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.702 million compared to USD 0.082 million a year ago. Net loss was USD 15.88 million compared to net income of USD 53.24 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to basic earnings per share from continuing operations of USD 1.38 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to diluted earnings per share from continuing operations of USD 0.76 a year ago.
For the nine months, sales was USD 0.929 million compared to USD 0.212 million a year ago. Net loss was USD 48.35 million compared to net income of USD 8.85 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 0.16 a year ago. Diluted loss per share from continuing operations was USD 0.62 compared to USD 0.16 a year ago.
Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Companyâs approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.
AKILI, INC. 
